Credit: Getty Images. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. Tepezza ® (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease (TED) ...

Findings showed a statistically significant reduction in proptosis in the linsitinib 150mg twice daily group, with a proptosis responder rate of 52% at week 24. Topline results were announced from a ...

Please provide your email address to receive an email when new articles are posted on . A 48-year-old man presented to the Lahey Eye Clinic as a new patient for care after recent head trauma while he ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

Researchers conducted an analysis of the THRIVE clinical trial to assess the safety and efficacy of veligrotug at week 15 in thyroid eye disease. Clinical Advisor, a trusted source of medical news and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 90-year-old woman was referred by her ophthalmologist ...

Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have identified new underlying mechanisms of proptosis, or bulging of the eyes, in patients with acute thyroid eye ...

Proptosis is the forward protrusion of a body part. Doctors typically use it to describe protruding or bulging eyeballs. Proptosis of the eyes can occur alongside swelling, double vision, and less ...

Viridian Therapeutics unveiled mixed results Tuesday for its experimental eye disease treatment, a potential rival to Amgen's ...